Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population.

Serwanga J, Mugaba S, Pimego E, Nanteza B, Lyagoba F, Nakubulwa S, Heath L, Nsubuga RN, Ndembi N, Gotch F, Kaleebu P.

AIDS Res Hum Retroviruses. 2012 Apr;28(4):384-92. doi: 10.1089/AID.2011.0175. Epub 2011 Oct 17.

2.

Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.

Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, Paranjape RS.

J Infect Dis. 2005 Sep 1;192(5):749-59. Epub 2005 Jul 27.

3.

Striking lack of T cell immunodominance in both a multiclade and monoclade HIV-1 epidemic: implications for vaccine development.

Tongo M, Zembe L, Ebong E, Roux S, Bekker LG, Williamson C, Mpoudi-Ngole E, Burgers WA.

Vaccine. 2014 Apr 25;32(20):2328-36. doi: 10.1016/j.vaccine.2014.02.063. Epub 2014 Mar 2.

PMID:
24598726
4.

Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects.

Côrtes FH, Bello G, Vorsatz C, Pilotto JH, Guimarães ML, Grinsztejn B, Veloso VG, Pinto AR, Morgado MG.

Vaccine. 2013 Feb 4;31(7):1106-12. doi: 10.1016/j.vaccine.2012.12.023. Epub 2012 Dec 20.

5.

[Specific immune responses to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins].

Zhai S, Kang WZ, Yu X, Wang SY, Walker BD, Altfeld M, Sun YT.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005 Mar;21(2):175-9. Chinese.

PMID:
15766402
6.

Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides.

Mugaba S, Nakiboneka R, Nanyonjo M, Bugembe-Lule D, Kaddu I, Nanteza B, Tweyongyere R, Kaleebu P, Serwanga J.

Vaccine. 2014 Jun 24;32(30):3787-95. doi: 10.1016/j.vaccine.2014.05.021. Epub 2014 May 14.

7.

Frequencies of Gag-restricted T-cell escape "footprints" differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B alleles.

Serwanga J, Nakiboneka R, Mugaba S, Magambo B, Ndembi N, Gotch F, Kaleebu P.

Vaccine. 2015 Mar 30;33(14):1664-72. doi: 10.1016/j.vaccine.2015.02.037. Epub 2015 Feb 26.

8.

Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.

Yang OO, Ali A, Kasahara N, Faure-Kumar E, Bae JY, Picker LJ, Park H.

J Virol. 2015 Jan 15;89(2):1195-204. doi: 10.1128/JVI.02370-14. Epub 2014 Nov 5.

9.

Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.

Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman KE, O'Callaghan CA, Ogg GS, Altfeld MA, Rosenberg ES, Cao H, Kalams SA, Hammond M, Bunce M, Pelton SI, Burchett SA, McIntosh K, Coovadia HM, Walker BD.

J Virol. 2000 Jun;74(12):5679-90.

10.

Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals.

Mendiratta S, Vajpayee M, Malhotra U, Kaushik S, Dar L, Mojumdar K, Chauhan NK, Sreenivas V.

Med Microbiol Immunol. 2009 Feb;198(1):47-56. doi: 10.1007/s00430-008-0104-3. Epub 2008 Nov 5.

PMID:
18985383
11.

Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.

Zembe L, Burgers WA, Jaspan HB, Bekker LG, Bredell H, Stevens G, Gilmour J, Cox JH, Fast P, Hayes P, Vardas E, Williamson C, Gray CM.

PLoS One. 2011;6(10):e26096. doi: 10.1371/journal.pone.0026096. Epub 2011 Oct 12.

12.

Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection.

Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, Reddy S, van der Stok M, Mncube Z, Nair K, Moodley ES, Kaufmann DE, Streeck H, Coovadia HM, Kiepiela P, Goulder PJ, Walker BD.

PLoS One. 2009;4(4):e5013. doi: 10.1371/journal.pone.0005013. Epub 2009 Apr 7.

13.

Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.

Almeida RR, Rosa DS, Ribeiro SP, Santana VC, Kallás EG, Sidney J, Sette A, Kalil J, Cunha-Neto E.

PLoS One. 2012;7(9):e45267. doi: 10.1371/journal.pone.0045267. Epub 2012 Sep 18.

14.

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.

Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, Mbewe B, Vardas E, Schechter M, Kallas EG, Freed DC, Fu TM, Mast CT, Puthavathana P, Kublin J, Brown Collins K, Chisi J, Pendame R, Thaler SJ, Gray G, Mcintyre J, Straus WL, Condra JH, Mehrotra DV, Guess HA, Emini EA, Shiver JW.

J Infect Dis. 2005 May 1;191(9):1427-34. Epub 2005 Mar 30.

15.

Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.

Barugahare B, Baker C, K'Aluoch O, Donovan R, Elrefaei M, Eggena M, Jones N, Mutalya S, Kityo C, Mugyenyi P, Cao H.

J Virol. 2005 Apr;79(7):4132-9.

16.

A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais.

Buranapraditkun S, Hempel U, Pitakpolrat P, Allgaier RL, Thantivorasit P, Lorenzen SI, Sirivichayakul S, Hildebrand WH, Altfeld M, Brander C, Walker BD, Phanuphak P, Hansasuta P, Rowland-Jones SL, Allen TM, Ruxrungtham K.

PLoS One. 2011;6(8):e23603. doi: 10.1371/journal.pone.0023603. Epub 2011 Aug 22.

17.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

19.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
20.

Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.

Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, Li F, Mesher AL, Robinson AD, Gottlieb GS, Huang Y, Kiviat NB.

J Virol. 2007 Sep;81(17):9061-71. Epub 2007 Jun 20.

Items per page

Supplemental Content

Write to the Help Desk